Related Experiment Video

Updated: Dec 19, 2025

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K

An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development

Sunita Shankar1,2, Jean Ching-Yi Tien1,2, Ronald F Siebenaler1,2

  • 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.

Nature Communications
|June 6, 2020
PubMed

Insights

Loss of Argonaute 2 (AGO2) in pancreatic cancer prevents tumor progression by inducing senescence. The KRAS-AGO2 interaction is crucial for pancreatic ductal adenocarcinoma (PDAC) development and is a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • KRAS and EGFR are key drivers in pancreatic cancer.
  • Argonaute 2 (AGO2) interacts with KRAS and EGFR, influencing their function.
  • Understanding AGO2's role is critical for pancreatic cancer research.

Purpose of the Study:

  • To investigate the role of AGO2 in pancreatic cancer development using a mutant KRAS mouse model.
  • To explore the interaction between KRAS and AGO2 in pancreatic ductal adenocarcinoma (PDAC) progression.
  • To identify potential therapeutic targets based on the KRAS-AGO2 interaction.

Main Methods:

  • Utilized a mouse model of mutant KRAS-driven pancreatic cancer.
  • Analyzed precursor lesions (PanIN) and pancreatic ductal adenocarcinoma (PDAC) tissues.
  • Investigated the effects of AGO2 ablation and p53 loss.
  • Examined RAS/AGO2 localization and AGO2 phosphorylation (Y393).
  • Assessed the impact of a KRAS G12C-specific inhibitor (ARS-1620).

Main Results:

  • Loss of AGO2 prevented PDAC progression, leading to senescence in precursor lesions.
  • AGO2 ablation altered microRNA expression and EGFR/RAS signaling, which was bypassed by p53 loss.
  • PDAC progression correlated with increased plasma membrane localization of RAS/AGO2.
  • Phosphorylation of AGO2 (Y393) affected KRAS-AGO2 interactions.
  • ARS-1620 disrupted the KRAS G12C-AGO2 interaction.

Conclusions:

  • Pancreatic cancer development follows a biphasic model involving AGO2.
  • An early, AGO2-independent phase involves EGFR-RAS signaling in PanIN formation.
  • A later, AGO2-dependent phase requires the mutant KRAS-AGO2 interaction for PDAC progression.
  • The KRAS-AGO2 interaction represents a potential therapeutic target for pancreatic cancer.

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.6K